Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis

Breast Cancer Research and Treatment

Volumn 143, Issue 3, 2014, Pages 435-446

  Ye, Tinghong ^a   Wei, Xiawei ^a,b   Yin, Tao ^a   Xia, Yong ^a   Li, Deliang ^a   Shao, Bin ^a   Song, Xuejiao ^a   He, Sisi ^a   Luo, Min ^a   Gao, Xiang ^a   He, Zhiyao ^a   Luo, Can ^a   Xiong, Ying ^a   Wang, Ningyu ^a   Zeng, Jun ^a   Zhao, Lifeng ^a   Shen, Guobo ^a   Xie, Yongmei ^a   Yu, Luoting ^a   Wei, Yuquan ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Breast cancer; FGFR; MDSCs; Metastasis; PD173074

Indexed keywords

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM METASTASIS; PYRIMIDINES; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894027173     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2829-y     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11-30
2. Weigelt B, Peterse JL, van't Veer LJ et al (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591-602
3. Kang YB, Siegel PM, Shu WP et al (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537-549
4. Minn AJ, Gupta GP, Siegel PM et al (2005) Genes that mediate breast cancer metastasis to lung. Nature 436:518-524
5. Zhang T, Li JJ, Dong YM et al (2012) Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion. Breast Cancer Res Treat 135:445-458
6. Aas T, Børresen AL, Geisler S et al (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 2:811-814
7. Doyle LA, Yang W, Abruzzo LV et al (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci 95:15665-15670
8. Kovalchuk O, Filkowski J, Meservy J et al (2008) Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7:2152-2159
9. Peters G, Brookes S, Smith R et al (1989) The mouse homolog of the hst/k-FGF gene is adjacent to int-2 and is activated by proviral insertion in some virally induced mammary tumors. Proc Natl Acad Sci 86:5678-5682
10. Ray ME, Yang ZQ, Albertson D et al (2004) Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines. Cancer Res 64:40-47
11. Reis-Filho JS, Simpson PT, Turner NC et al (2006) FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 12:6652-6662
12. Hynes NE, Dey JH (2010) Potential for targeting the fibroblast growth factor receptors in breast cancer. Cancer Res 70:199-5202
13. Zhao GS, Li WY, Chen DH et al (2011) A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther 10:2200-2210
14. Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10:116-129
15. Klint P, Claesson-Welsh L (1999) Signal transduction by fibroblast growth factor receptors. Front Biosci 4:165-177
16. Gavine PR, Mooney L, Kilgour E et al (2012) AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor Tyrosine kinase family. Cancer Res 72:2045-2056
17. Martinez-Torrecuadrada J, Cifuentes G, Lopez-Serra P et al (2005) Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res 11:6280-6290
18. Liang G, Liu ZG, Wu JZ et al (2012) Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol Sci 33:531-541
19. Jorgen W, Kaise H, Ellen MH et al (2011) Fibroblast growth factors and their receptors in cancer. Biochem J 437:199-213
20. Dey JH, Bianchi F, Voshol J et al (2010) Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 70:4151-4162
21. Issa A, Gill JW, Heideman MR et al (2013) Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models. Breast Cancer Res 15:R8
22. Mohammadi M, Froum S, Hamby JM et al (1998) Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 17:5896-5904
23. Pardo OE, Latigo J, Jeffery RE et al (2009) The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res 69:8645-8651
24. Sharpe R, Pearson A, Herrera-Abreu MT et al (2011) FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res 17:5275-5286
25. Kortylewski M, Swiderski P, Herrmann A et al (2009) In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nature Biotech 27:925-932
26. Kim S, Takahashi H, Lin WW et al (2009) Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457:102-106
27. Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182:4499-4506
28. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162-174
29. Kodumudi KN, Woan K, Gilvary DL et al (2010) A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 16:4583-4594
30. Xu YZ, Zheng RL, Zhou Y et al (2011) Small molecular anticancer agent SKLB703 induces apoptosis in human hepatocellular carcinoma cells via the mitochondrial apoptotic pathway in vitro and inhibits tumor growth in vivo. Cancer Lett 313:44-53
31. Kortylewski M, Kujawski M, Wang TH et al (2011) Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11:1314-1321
32. Wu WS, Ye HY, Li Wan et al (2013) Millepachine, a novel chalcone, induces G2/M arrest by inhibiting CDK1 activity and causing apoptosis via ROS-mitochondrial apoptotic pathway in human hepatocarcinoma cells in vitro and in vivo. Carcinogenesis 34:1636-1643
33. Xin H, Herrmann A, Reckamp K et al (2011) Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res 71:6601-6610
34. Kujawski M, Kortylewski M, Lee H et al (2008) Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118:3367-3377
35. Albini A, Sporn MB (2007) The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 7:139-147
36. Pulaski BA, Ostrand-Rosenberg S (1998) Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 58:1486-1493
37. Pulaski BA, Terman DS, Khan S et al (2000) Cooperativity of staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 60:2710-2715
38. Wang YS, Li D, Shi HS et al (2009) Intratumoral expression of mature human neutrophil peptide-1 mediates antitumor immunity in mice. Clin Cancer Res 15:6901-6911
39. Koziczak M, Holbro T, Hynes NE et al (2004) Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 23:3501-3508
40. Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411:342-348
41. Dimitroff CJ, Klohs W, Sharma A et al (1999) Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs 17:121-135
42. Bui JD, Schreiber RD et al (2007) Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 19:203-208
43. Koebel CM, Vermi W, Swann JB et al (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903-907
44. Zou WP (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263-274
45. Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41-51
46. Yang L, Huang JH, Ren XB et al (2008) Abrogation of TGFβ signaling in mammary carcinomas recruits Gr-1+ CD11b+ myeloid cells that promote metastasis. Cancer Cell 13:23-35
47. Nagaraj S, Gabrilovich DI (2010) Myeloid-derived suppressor cells in human cancer. Cancer J 16:38-353
48. Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127:679-695
49. Hiratsuka S, Watanabe A, Aburtani H et al (2006) Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8:1369-1375
50. Gao DC, Joshi N, Ryu S et al (2012) Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res 72:1384-1394